JP Morgan Initiates Coverage On Iambic Therapeutics with Overweight Rating, Announces Price Target of $22
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsInitiationPrice Target
JP Morgan initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Overweight rating and announces Price Target of $22.
JP Morgan initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Overweight rating and announces Price Target of $22.